Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status - PubMed (original) (raw)
Review
Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status
H Bonkhoff. Ann Oncol. 2001.
Free article
Abstract
Background: The frequent occurrence of neuroendocrine (NE) differentiation in common prostatic malignancies has attracted increasing attention in contemporary prostate cancer research.
Methods: The present review focuses on growth properties and the androgen receptor (AR) status of NE phenotypes, and discusses their morphogenetic origin in benign and malignant prostate tissue.
Results: Recent data have documented a phenotype link between NE cells and other cell lineages encountered in benign and malignant prostate tissue. NE tumor cells (as defined by the most commonly used endocrine marker chromogranin A) do not proliferate or show apoptotic activity. This particular phenotype also lacks the nuclear AR in both benign and malignant conditions.
Conclusions: Prostatic NE cells most likely derive from local stem cells and represent terminally differentiated and androgen-insensitive cell populations in benign prostate tissue. The frequent occurrence of NE differentiation in prostatic adenocarcinoma obviously reflects the differentiation repertoire of its stem cells. Neoplastic NE cells devoid of nuclear AR constitute an androgen-insensitive cell population in prostate cancer. The absence of proliferative and apoptotic activity may endow NE tumor cells with relative resistance towards cytotoxic drugs and radiation therapy.
Similar articles
- [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
Bonkhoff H, Fixemer T. Bonkhoff H, et al. Urologe A. 2004 Jul;43(7):836-42. doi: 10.1007/s00120-004-0559-9. Urologe A. 2004. PMID: 15048555 Review. German. - [Neuroendocrine differentiation in prostate cancer: an unrecognized and therapy resistant phenotype].
Bonkhoff H, Fixemer T. Bonkhoff H, et al. Pathologe. 2005 Nov;26(6):453-60. doi: 10.1007/s00292-005-0791-0. Pathologe. 2005. PMID: 16195860 German. - Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schröder FH, van Steenbrugge GJ. Jongsma J, et al. Cancer Res. 2000 Feb 1;60(3):741-8. Cancer Res. 2000. PMID: 10676662 - Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
Bonkhoff H, Remberger K. Bonkhoff H, et al. Prostate. 1996 Feb;28(2):98-106. doi: 10.1002/(SICI)1097-0045(199602)28:2<98::AID-PROS4>3.0.CO;2-J. Prostate. 1996. PMID: 8604398 Review.
Cited by
- SIRT1 contributes to neuroendocrine differentiation of prostate cancer.
Ruan L, Wang L, Wang X, He M, Yao X. Ruan L, et al. Oncotarget. 2017 Dec 11;9(2):2002-2016. doi: 10.18632/oncotarget.23111. eCollection 2018 Jan 5. Oncotarget. 2017. PMID: 29416748 Free PMC article. - The steroid receptor coactivator-3 is required for developing neuroendocrine tumor in the mouse prostate.
Tien JC, Liao L, Liu Y, Liu Z, Lee DK, Wang F, Xu J. Tien JC, et al. Int J Biol Sci. 2014 Oct 2;10(10):1116-27. doi: 10.7150/ijbs.10236. eCollection 2014. Int J Biol Sci. 2014. PMID: 25332686 Free PMC article. - SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer.
Bloom JE, McNeel DG. Bloom JE, et al. Oncotarget. 2016 Aug 9;7(32):50997-51011. doi: 10.18632/oncotarget.9802. Oncotarget. 2016. PMID: 27276714 Free PMC article. - EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Martín-Orozco RM, Almaraz-Pro C, Rodríguez-Ubreva FJ, Cortés MA, Ropero S, Colomer R, López-Ruiz P, Colás B. Martín-Orozco RM, et al. Neoplasia. 2007 Aug;9(8):614-24. doi: 10.1593/neo.07337. Neoplasia. 2007. PMID: 17898861 Free PMC article. - Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients.
Deng X, Elzey BD, Poulson JM, Morrison WB, Ko SC, Hahn NM, Ratliff TL, Hu CD. Deng X, et al. Am J Cancer Res. 2011;1(7):834-44. Epub 2011 Aug 18. Am J Cancer Res. 2011. PMID: 22016831 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials